NCT07285694 AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
| NCT ID | NCT07285694 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Arsenal Biosciences, Inc. |
| Condition | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 190 participants |
| Start Date | 2026-01-09 |
| Primary Completion | 2029-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 190 participants in total. It began in 2026-01-09 with a primary completion date of 2029-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Eligibility Criteria
Key Inclusion Criteria: 1. At least 18 years of age at time of signing informed consent form. 2. Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria: • Documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on PCWG3 criteria. 3. Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy. • PSMA+ by PSMA PET. * Measurable disease by RECIST 1.1 criteria, or evaluable disease via measurable PSA (≥ 1 ng/mL) per PCWG3 criteria. 4. Adequate organ functions. Key Exclusion Criteria: 1. Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis. 2. Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression. 3. Unwillingness to participate in an extended safety monitoring period.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07285694 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Castration Resistant Prostate Cancer (mCRPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07285694 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07285694 currently recruiting?
Yes, NCT07285694 is actively recruiting participants. Contact the research team at clinicaltrials@arsenalbio.com for enrollment information.
Where is the NCT07285694 trial being conducted?
This trial is being conducted at Duarte, United States, Los Angeles, United States, San Francisco, United States, Iowa City, United States and 4 additional locations.
Who is sponsoring the NCT07285694 clinical trial?
NCT07285694 is sponsored by Arsenal Biosciences, Inc.. The trial plans to enroll 190 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.